BlackRock Amends Arbutus Biopharma Stake, Maintains Passive Position

Ticker: ABUS · Form: SC 13G/A · Filed: 2024-02-12T00:00:00.000Z

Sentiment: neutral

Topics: institutional-ownership, amendment, passive-investment

TL;DR

**BlackRock still holds Arbutus Biopharma stock, signaling continued institutional interest.**

AI Summary

BlackRock Inc. filed an amended SC 13G/A on February 12, 2024, indicating its ownership of Arbutus Biopharma Corp's Common Stock as of December 31, 2023. This filing updates their previous disclosure, showing BlackRock continues to hold a significant passive stake in Arbutus Biopharma. This matters to investors because BlackRock's continued substantial holding signals confidence in the company's long-term prospects, potentially influencing other institutional investors and providing a degree of stability to the stock.

Why It Matters

BlackRock's updated filing confirms its ongoing significant, passive investment in Arbutus Biopharma, which can be seen as a vote of confidence from a major institutional investor.

Risk Assessment

Risk Level: low — This filing is a routine update from a passive institutional investor and does not indicate any immediate change in strategy or significant risk.

Analyst Insight

Investors should note BlackRock's continued passive stake as a sign of institutional presence, but this filing alone doesn't suggest a need for immediate action. It's a routine update confirming existing investment.

Key Players & Entities

FAQ

What type of filing is this document?

This document is an SC 13G/A, which is an amendment to a Schedule 13G filing, as stated in the 'FORM TYPE: SC 13G/A' and 'Under the Securities Exchange Act of 1934 (Amendment No: 1)' sections.

Who is the subject company of this filing?

The subject company is Arbutus Biopharma Corp, as indicated under 'SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: Arbutus Biopharma Corp'.

Who is the entity that filed this SC 13G/A?

The entity that filed this SC 13G/A is BlackRock Inc., as stated under 'FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: BlackRock Inc.'.

What was the date of the event that required this filing?

The date of the event which required this filing was December 31, 2023, as specified under '(Date of Event Which Requires Filing of this Statement)'.

Under which rule was this Schedule 13G filed?

This Schedule 13G was filed under Rule 13d-1(b), as indicated by the '[X] Rule 13d-1(b)' checkbox.

From the Filing

0001086364-24-006950.txt : 20240212 0001086364-24-006950.hdr.sgml : 20240212 20240212094146 ACCESSION NUMBER: 0001086364-24-006950 CONFORMED SUBMISSION TYPE: SC 13G/A PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20240212 DATE AS OF CHANGE: 20240212 SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: Arbutus Biopharma Corp CENTRAL INDEX KEY: 0001447028 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 980597776 STATE OF INCORPORATION: A1 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13G/A SEC ACT: 1934 Act SEC FILE NUMBER: 005-85963 FILM NUMBER: 24617750 BUSINESS ADDRESS: STREET 1: 701 VETERANS CIRCLE CITY: WARMINSTER STATE: PA ZIP: 18974 BUSINESS PHONE: 604-419-3200 MAIL ADDRESS: STREET 1: 701 VETERANS CIRCLE CITY: WARMINSTER STATE: PA ZIP: 18974 FORMER COMPANY: FORMER CONFORMED NAME: TEKMIRA PHARMACEUTICALS Corp DATE OF NAME CHANGE: 20110607 FORMER COMPANY: FORMER CONFORMED NAME: TEKMIRA PHARMACEUTICALS CORP DATE OF NAME CHANGE: 20081003 FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: BlackRock Inc. CENTRAL INDEX KEY: 0001364742 STANDARD INDUSTRIAL CLASSIFICATION: SECURITY BROKERS, DEALERS & FLOTATION COMPANIES [6211] ORGANIZATION NAME: 02 Finance IRS NUMBER: 320174431 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13G/A BUSINESS ADDRESS: STREET 1: 50 HUDSON YARDS CITY: NEW YORK STATE: NY ZIP: 10001 BUSINESS PHONE: 212-810-5300 MAIL ADDRESS: STREET 1: 50 HUDSON YARDS CITY: NEW YORK STATE: NY ZIP: 10001 FORMER COMPANY: FORMER CONFORMED NAME: BlackRock, Inc. DATE OF NAME CHANGE: 20060929 FORMER COMPANY: FORMER CONFORMED NAME: New BlackRock, Inc. DATE OF NAME CHANGE: 20060601 SC 13G/A 1 ca03879j1003_021224.txt ca03879j1003_021224.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: 1) Arbutus Biopharma Corp -------------------------------------------------------- (Name of Issuer) Common Stock -------------------------------------------------------- (Title of Class of Securities) BZ0QMB7 -------------------------------------------------------- (SEDOL Number) December 31, 2023 -------------------------------------------------------- (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [X] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page. The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes). SEDOL No. BZ0QMB7 (1)Names of reporting persons. BlackRock, Inc. (2) Check the appropriate box if a member of a group (a) [ ] (b) [X] (3) SEC use only (4) Citizenship or place of organization Delaware Number of shares beneficially owned by each reporting person with: (5) Sole voting power 10255443 (6) Shared voting power 0 (7) Sole dispositive power 10390300 (8) Shared dispositive power 0 (9) Aggregate amount beneficially owned by each reporting person 10390300 (10) Check if the aggregate amount in Row (9) excludes certain shares (11) Percent of class represented by amount in Row 9 6.2% (12) Type of reporting person HC Item 1. Item 1(a) Name of issuer: ----------------------------------------------------------------------- Arbutus Biopharma Corp Item 1(b) Address of issuer's principal executive offices: ----------------------------------------------------------------------- 701 Veterans Circle Warminster PA 18974 Item 2. 2(a) Name of per

View on Read The Filing